| Value | ₹1.19 Cr |
|---|
BSE filing, NSE: BROOKS. Summary written from the filing by ALFA Finder's alert engine.
Brooks Laboratories Ltd: key numbers
- Share price
- ₹64.98
- Market cap
- ₹191.4 Cr
- Revenue (annual)
- ₹85.74 Cr
- Net profit (annual)
- ₹24.58 Cr
- P/E (TTM)
- 14.5×Sector 41.3×
- Promoter holding
- 52.62%+0.00% QoQ
- FII holding
- 0.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Brooks Laboratories Ltd
All →Brooks Laboratories Board Meeting Date
Brooks Laboratories will hold a board meeting on 7 November 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. The trading window is closed until 9 November 2026.
Brooks Laboratories Other Announcement
Brooks Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI regulatory requirements.
Brooks Laboratories Merger & Restructuring
Brooks Laboratories approved a demerger of its Manufacturing Business into its wholly-owned subsidiary, Abridge Speciality Limited, through a scheme of arrangement.
Brooks Laboratories Price Movement Clarification
Brooks Laboratories informed BSE it has no additional material information to disclose regarding the recent price movement. The company attributed the share price and volume changes to purely market-driven factors.
Brooks Laboratories Management Change
Brooks Laboratories Ltd announced the resignation of Ms. Krutika Rane, Company Secretary and Compliance Officer, effective October 9, 2026.
Brooks Laboratories Annual General Meeting
Brooks Laboratories Limited conducted its 24th Annual General Meeting on September 3, 2026. Shareholders transacted ordinary business, including the adoption of financial statements and director appointments.
Other debt & borrowing announcements
All →Max Estates Debt & Borrowing: ₹350 Cr
Max Estates' board approved a ₹350 crore corporate guarantee for a wholly-owned subsidiary's term loan. Monitoring agency reports on its QIP and warrant proceeds were also filed.
- Value
- ₹350.0 Cr
Credent Connect N Care Debt & Borrowing: ₹4.5 Cr
Credent Connect N Care's board approved an unsecured inter-corporate loan of Rs 4.50 Crore to Kartavya Healtheon Private Limited. The loan carries 12% compounded interest after 25 November 2026 and gives the lender a right to up to 26% equity.
- Value
- ₹4.50 Cr
Amines & Plasticizers Debt & Borrowing
Amines & Plasticizers invited members to place unsecured deposits under Form DPT-1. Only resident members may subscribe, and the scheme is on the company website.
HEG Advanced Materials Debt & Borrowing: ₹50 Cr
HEG granted subsidiary Replus Engitech an unsecured revolving loan of Rs.50 Crore. It is repayable on demand at 9% interest, at arm's length.
- Value
- ₹50.00 Cr
- Execution
- Repayable on demand
Purple Finance Debt & Borrowing: ₹25 Cr
Purple Finance's finance committee approved issuing up to 25,000 senior secured NCDs aggregating ₹25 Crore on a private placement basis. The debentures carry an 11.50% coupon and a 30-month tenure.
- Value
- ₹25.00 Cr
- Execution
- 30 months from deemed date of allotment
Bloom Industries Debt & Borrowing: ₹113 Cr
Bloom Industries approved pledging 9.40% of Shivom Minerals shares to secure ₹113 Crore NCDs and convened an EGM. The company states no material adverse operational impact.
- Value
- ₹113.0 Cr